In summary, the present study comprehensively analyzed FXYD2 expression in ccRCC utilizing several public datasets and our clinical tissue samples and demonstrated that downregulated FXYD2 expression correlated with carcinogenesis, poor prognosis, and increased Treg infiltration in ccRCC, which may function by participating in TGF-β-SMAD2/3, Notch, and PI3K-Akt-mTOR signaling pathways. The gene discussed is FXYD2; the disease is nonpapillary renal cell carcinoma.